Argenx Se (ARGX) Accounts Payables (2015 - 2026)
Argenx Se's (ARGX) quarterly Accounts Payables came in at $1.5 billion in Q2 2026, down 99.85% on a YoY basis from $1016.2 billion in Q2 2025, and up 19.57% quarter-over-quarter from $1.3 billion in Q4 2025.
Analysis
Argenx Se (ARGX) Accounts Payables (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Accounts Payables for 12 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Accounts Payables fell 99.85% year-over-year to $1.5 billion; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (down 99.85% YoY), and the FY2025 full-year result was $1.3 billion, down 99.81% from the prior year.
- Accounts Payables grew to $1.5 billion in Q2 2026 per ARGX's latest filing, from $1.3 billion in the prior quarter.
- Across five years, Accounts Payables topped out at $1016.2 billion in Q2 2025 and bottomed at $257.7 million in Q2 2022.
- Historically, Accounts Payables has averaged $218.5 billion across 5 years, with a median of $1.3 billion in 2025.
- The sharpest annual moves came in 2023 and 2025: Accounts Payables slumped 99.86% in 2023, then surged 211675.45% in 2025.
- Over 5 years, Accounts Payables stood at $295.7 billion in 2022, then plunged by 99.86% to $414.0 million in 2023, then soared by 156898.21% to $650.0 billion in 2024, then sank by 99.81% to $1.3 billion in 2025, then climbed by 19.57% to $1.5 billion in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.5 billion, $1.3 billion, and $1016.2 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 428.93 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 751.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.52 Bn |
| Dec 31, 2025 | 1.27 Bn |
| Jun 30, 2025 | 1,016.16 Bn |
| Dec 31, 2024 | 649.99 Bn |
| Jun 30, 2024 | 479.83 Mn |
| Dec 31, 2023 | 414.01 Mn |
| Jun 30, 2023 | 309.99 Mn |
| Dec 31, 2022 | 295.68 Bn |
| Jun 30, 2022 | 257.69 Mn |
| Dec 31, 2021 | 293.42 Bn |
| Jun 30, 2021 | 239.44 Mn |
| Dec 31, 2020 | 267.39 Bn |
| Jun 30, 2020 | 140.82 Mn |
| Dec 31, 2019 | 94.42 Mn |
| Jun 30, 2019 | 61.88 Mn |
| Dec 31, 2018 | 42.31 Mn |
| Jun 30, 2018 | 25.73 Mn |
| Dec 31, 2017 | 18.00 Mn |
| Jun 30, 2017 | 14.37 Mn |
| Dec 31, 2016 | 13.16 Mn |